Evidence map›Paper›PMID 33501430›Full record

ArticleNeuro-oncology advances

The brain tumor not-for-profit and charity experience of COVID-19: reacting and adjusting to an unprecedented global pandemic in the 21st century.

Christina Amidei, Jean Arzbaecher, Mary Ellen Maher, Christine Mungoshi, Rosemary Cashman, Stuart Farrimond, Carol Kruchko, Chris Tse, Maureen Daniels, Sharon Lamb and 5 more

Open access · goldAbstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. How has the COVID-19 pandemic impacted clinical care and research in Neuro-Oncology?Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2022
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 4 countries.

Christina AmideiDepartment of Neurological Surgery, Feinberg School of Medicine, Northwestern Medicine, Chicago, Illinois, USA.
Jean ArzbaecherBrain Tumor Center, Department of Neurology and Rehabilitation, University of Illinois, Chicago, Illinois, USA.
Mary Ellen MaherLou and Jean Malnati Brain Tumor Institute, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern Medicine, Chicago, Illinois, USA.
Christine MungoshiZimbabwe Brain Tumour Association, Harare, Zimbabwe.
Rosemary CashmanBC Cancer Agency, Vancouver, British Columbia, Canada.
Stuart FarrimondInternational Brain Tumour Alliance (IBTA), Tadworth, UK.
Carol KruchkoCentral Brain Tumor Registry of the United States (CBTRUS), Hinsdale, Illinois, USA.ORCID 0000-0001-7212-035X
Chris TseInternational Brain Tumour Alliance (IBTA), Tadworth, UK.
Maureen DanielsThe Gerry & Nancy Pencer Brain Tumour Centre, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Sharon LambInternational Brain Tumour Alliance (IBTA), Tadworth, UK.
Anita GraneroOscar's Angels, Toulouse, France and Rome, Italy.
Mary LovelyNational Brain Tumor Society, Newton, Massachusetts, USA.
Jenifer BakerInternational Brain Tumour Alliance (IBTA), Tadworth, UK.
Sally PayneInternational Brain Tumour Alliance (IBTA), Tadworth, UK.
Kathy OliverInternational Brain Tumour Alliance (IBTA), Tadworth, UK.
Brain Tumour Charity · GBBC Cancer Agency · CACentral Brain Tumor Registry of the United States · USIstituto De Angeli (Italy) · ITNational Brain Tumor Society · USNorthwestern Medicine · USNorthwestern University · USUniversity Health Network · CAUniversity of Illinois Urbana-Champaign · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Coronavirus Disease 2019 (COVID-19) pandemic has affected individuals as well as disease-specific brain tumor organizations. These organizations around the world exist to address unmet needs for patients and caregivers they serve. The direct impact of the pandemic on these organizations constitutes significant collateral damage. In order to better understand the effects of the COVID-19 pandemic on brain tumor organizations, the International Brain Tumour Alliance (IBTA) carried out an international survey to identify organizational changes induced by the virus and approaches adopted to address challenges.

methodsA 37-question online survey consisting of categorical and qualitative questions was developed and circulated to 130 brain tumor organizations across the world. Seventy-seven organizations from 22 countries completed the survey (59% return rate). Descriptive statistics and content analysis were used to present the results.

resultsResponses fell into the following 3 categories: (1) organizational characteristics, (2) impact of COVID-19 on services, and (3) COVID-19 impact on financial and human resources within organizations. Although organizational characteristics varied, common concerns reported were activity disruption which impacted organizations' abilities to offer usual services and challenges to sustaining funding. Both financial and human resources were stressed, but integral adaptations were made by organizations to preserve resources during the pandemic.

conclusionsAlthough brain tumor organizations have been impacted by the COVID-19 pandemic, organizations quickly adjusted to this unprecedented global healthcare crisis. Nimble reactions and flexibility have been vital to organization sustainability. Innovative approaches are required to ensure organizations remain viable so that needs of brain tumor community at large are met.

Indexed as

brain tumor organizationCOVID-19support services

Identifiers

PMID33501430
PMCPMC7798794
OpenAlexW3113328907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.